CompletedPhase 2NCT00045734

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

Studying Meningioma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Patrick Wen, MD, MD, PHD
North American Brain Tumor Consortium
Intervention: imatinib mesylate(drug)
Enrollment: 23 enrolled
Eligibility: 18 years · All sexes
Timeline: 2003 – 2009

Study locations (7)

University of California Los Angeles, Los Angeles, California, United States
University of California San Francisco, San Francisco, California, United States
National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
University of Wisconsin, Madison, Wisconsin, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00045734 on ClinicalTrials.gov

Other trials for Meningioma

Additional recruiting or active studies for the same condition.

See all trials for Meningioma →

← Back to all trials